Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piers J Ingram

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Plos Computational Biology|January 24, 2013
An integrative model of ion regulation in yeastRuian Ke, Piers J Ingram, Ken Haynes
BMC Genomics|May 9, 2006
Network motifs: structure does not determine functionPiers J Ingram, Michael P H Stumpf, Jaroslav Stark
Plos Computational Biology|October 11, 2008
Nonidentifiability of the source of intrinsic noise in gene expression from single-burst dataPiers J Ingram, Michael P H Stumpf, Jaroslav Stark
Methods in Molecular Biology (Clifton, N.J.)|December 7, 2011
The degree distribution of networks: statistical model selectionWilliam P Kelly, Piers J Ingram, Michael P H Stumpf
Molecular Cancer Therapeutics|January 9, 2020
10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor ModelsDipti Thakkar, Vicente Sancenon, Marvin M Taguiam, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent mannerDipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, et al.
Infectious Diseases and Therapy|September 4, 2022
First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy AdultsVenkateshan S Prativadibhayankaram, Lawrence Soon-U Lee, David Lye, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Plos Computational Biology|January 24, 2013
An integrative model of ion regulation in yeastRuian Ke, Piers J Ingram, Ken Haynes
BMC Genomics|May 9, 2006
Network motifs: structure does not determine functionPiers J Ingram, Michael P H Stumpf, Jaroslav Stark
Plos Computational Biology|October 11, 2008
Nonidentifiability of the source of intrinsic noise in gene expression from single-burst dataPiers J Ingram, Michael P H Stumpf, Jaroslav Stark
Methods in Molecular Biology (Clifton, N.J.)|December 7, 2011
The degree distribution of networks: statistical model selectionWilliam P Kelly, Piers J Ingram, Michael P H Stumpf
Molecular Cancer Therapeutics|January 9, 2020
10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor ModelsDipti Thakkar, Vicente Sancenon, Marvin M Taguiam, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent mannerDipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, et al.
Infectious Diseases and Therapy|September 4, 2022
First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy AdultsVenkateshan S Prativadibhayankaram, Lawrence Soon-U Lee, David Lye, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 1